

Shu et al, CID

DNAm mediates cocaine exposure on HIV

1 **DNA methylation mediates the effect of cocaine use on HIV severity**

2

3 Chang Shu^{1,2}, Amy C. Justice^{2,3}, Xinyu Zhang^{1,2}, Zuoheng Wang⁴, Dana B. Hancock⁵, Eric O.

4 Johnson^{5,6}, Ke Xu^{1,2}

5 1. Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA

6 2. Connecticut Veteran Healthcare System, West Haven, CT, USA

7 3. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

8 4. Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA

9 5. Center for Omics Discovery and Epidemiology, Behavioral Health Research Division,

10 RTI International, Research Triangle Park, NC, USA

11 6. Fellow Program, RTI International, Research Triangle Park, NC, USA.

12

13 **Keywords:** Cocaine use, HIV severity, mortality, DNA methylation, mediation effect

14 **Running title:** DNA methylation mediates cocaine exposure on HIV

15 Word count:

16 Abstract: 237; Text: 2989

17 Figure: 4

18 Table: 5

19 **Corresponding Author**

20 Ke Xu, MD., Ph.D.

21 Associate Professor of Psychiatry

22 Yale School of Medicine

23 950 Campbell Ave, West Haven, CT

24 Email: ke.xu@yale.edu

25 Tel: 203-932-5711 x7430

26

27 **Abstract**

28 **Background:** Cocaine use accelerates HIV progression and worsens HIV outcomes. We
29 assessed whether DNA methylation (DNAm) in blood mediates the association between
30 cocaine use and HIV severity in a veteran population.

31 **Methods:** We analyzed 1,435 HIV-positive participants from the Veterans Aging Cohort Study
32 Biomarker Cohort. HIV severity was measured by the Veteran Aging Cohort Study index (VACS
33 index). We assessed the effect of cocaine use on VACS index and mortality among the HIV-
34 positive participants. We selected candidate mediators from 408,583 CpGs that were both
35 significantly associated with persistent cocaine use and VACS index by epigenome-wide
36 association (EWA) scans. Mediation analysis was conducted on the selected CpGs and joint
37 mediation effect of multiple CpGs were estimated.

38 **Results:** More frequent cocaine use was significantly associated with higher VACS index
39 ($p=2.7E-04$) and cocaine use increased the risk of 10-year mortality (hazard ratio=1.10, $p=0.011$)
40 with adjustment of confounding factors. Based on the EWA scan, 15 candidate mediator CpGs
41 were selected and 12 CpGs showed significant mediation effect with each explained 11.3%-
42 29.5% of the variation. The joint mediation effect of these 12 CpGs accounted for 47.2% of
43 cocaine's effect on HIV severity. Genes harboring these 12 CpGs are involved in antiviral
44 response (*IFIT3*, *IFITM1*, *NLRC5*, *PLSCR1*, *PARP9*) and HIV progression (*CX3CR1*, *MX1*).
45 Furthermore, these genes were enriched in pathways involving in viral process ($p=7.76E-08$)
46 and response to cytokine ($p=9.88E-07$).

47 **Conclusions:** DNAm played a mediation role between cocaine use and HIV severity.

48

49 **Introduction**

50 Cocaine use is highly prevalent among persons with chronic HIV infection [1, 2]. Previous
51 studies have shown that cocaine use accelerated HIV progression [3-6]. However, the biological
52 mechanism of cocaine's effect on HIV outcomes remains largely unknown. Some studies have
53 suggested that cocaine use may worsen HIV outcomes due to poor adherence to antiretroviral
54 therapy (ART) among HIV-positive participants [7, 8]. Other studies have demonstrated that
55 cocaine's adverse effect on HIV outcomes is independent of ART [5, 6, 9-11], supporting the
56 hypothesis that cocaine exposure may lead to long-lasting pathophysiological changes in the
57 immune system that worsen HIV outcomes.

58 DNA methylation (DNAm) is an important mechanisms that haven been shown to associated
59 with many environmental exposures such as smoking and alcohol[12-21], and diseases such as
60 cancer, diabetes and cardiovascular diseases [22-27]. Our previous study showed that two
61 DNAm sites in *NLRC5* was differentially methylated between HIV-positive and HIV-negative
62 participants in peripheral blood [28]. More importantly, DNAm may play a mediation role linking
63 environmental exposure and disease outcomes [29-35]. A recent study reported that DNAm
64 sites in *PIM3* (energy metabolism) and *ABCG1* (lipid metabolism) mediated the association
65 between prenatal famine exposure and long-term metabolic outcomes [33]. Another study
66 reported the mediation effect of cg05575921 (*AHRR*) between smoking and the risk of bladder
67 cancer among postmenopausal women [36].

68
69 Previous studies have shown that the use of cocaine enhances HIV-1 replication and
70 undermines immune function by dysregulating gene expression on HIV-1 entry co-receptors,
71 enhancing HIV-1 cellular toxicity and dysregulating interleukins in the host [37, 38]. However, no
72 studies have examined the role of DNAm on how cocaine exposure worsens HIV outcomes. We
73 hypothesized that DNAm may mediate the effect of cocaine exposure on HIV severity.

74

75 In this study, we first validated previous findings by examining cocaine's adverse effect on HIV
76 severity and mortality. We further conducted a mediation analyses to assess the mediation role
77 of DNAm sites (or CpGs) on cocaine's effect on HIV severity using the Veteran Aging Cohort
78 Study – Biomarker Cohort (VACS-BC). Lastly, we examined genes and biological pathways
79 related with these CpGs. Our results provide new insights for the role of DNAm on how cocaine
80 affects HIV severity.

81

82 **Methods**

83 **Study samples:** The Veteran Aging Cohort Study (VACS) is a prospective cohort study of
84 veterans designed to study substance use and HIV related outcomes with patient surveys,
85 electronic medical records and biospecimen data [39]. Baseline survey was conducted at the
86 enrollment[39]. The follow-up survey of 5 visits occurred in approximately one-year interval [39].
87 Blood samples were collected in the middle of follow-up for a subset of participants in the cohort
88 (VACS-BC) [40]. A total of 1,435 HIV-positive participants from the VACS-BC were used to
89 examine cocaine's effect on mortality and HIV severity, and a subset of samples (N=875) with
90 DNAm data available were used for mediation analyses (**Figure 1**). Demographic and clinical
91 information of baseline samples and a subset of the samples at the time of blood collection are
92 summarized in **Table 1**.

93

94 **Assessment of cocaine use:** The timeline of cocaine use assessment for each analysis is
95 illustrated in **Figure 1**. Information on cocaine use status was self-reported through telephone
96 interview for a total of 5 visits. We defined the “persistent cocaine use” group as self-reported
97 cocaine use across all 5 visits, and “no cocaine use” group with self-reported no cocaine use
98 across all 5 visits. This definition led to a subset of samples with 265 persistent cocaine users

99 and 202 non-users for the mediation analyses to eliminate the inconsistent response across 5
100 visits and examine the effect of long-term cocaine exposure on DNAm and HIV severity.
101 The frequency of cocaine use was also assessed at baseline (**Figure 1**). Each participant was
102 asked “how often in the past year have you used cocaine or crack?”, from which cocaine
103 frequency of use was coded as an ordinal variable: 0=never tried; 1= no use in the last year;
104 2=less than once a month; 3=1-3 times a month; 4=1-3 times a week, and 5=4 or more times a
105 week.

106

107 **Assessment of mortality and HIV severity:** The timeline of HIV severity measurement and
108 survival information for each analysis is shown in **Figure 1**. Mortality and survival year
109 information were based on medical records. VACS index was used as a measure of HIV
110 severity [41-44] and was obtained at each visit and at the time of blood collection (**Figure 1**).
111 The VACS index was calculated by summing pre-assigned points for age, routinely monitored
112 indicators of HIV disease (CD4 count and HIV-1 RNA) and other general indicators of organ
113 system injury [41]. High VACS index corresponds to worsened HIV outcomes and VACS index
114 is positively associated with increased mortality [45]. VACS index at same time with DNAm
115 profiling was used for the selection of candidate mediator CpGs, and the average VACS index
116 after the blood collection was used for mediation analyses (**Figure 1**).

117

118 **DNA methylation profiling and quality control:** DNA samples were extracted from blood for a
119 subset of 875 HIV-positive participants (**Figure 1**). DNAm was profiled using two different
120 methylation arrays, with 475 samples profiled by the Infinium Human Methylation 450K
121 BeadChip (HM450K) and 400 samples profiled by the Infinium Human Methylation EPIC
122 BeadChip (EPIC) [40]. DNA samples were randomly selected for each methylation array
123 regardless of cocaine use status or other clinical demographic variables.

124

125 Quality control (QC) for samples measured by each array was conducted separately using the
126 same pipeline as previously described [46] by the R package *minfi* [47]. After QC, a total of
127 408,583 CpGs were measured by both the HM450k and EPIC array remained for analysis. Six
128 cell type proportions (CD4+ T cells, CD8+ T cells, NK T cells, B cells, monocytes and
129 granulocytes) were estimated for each participant using the established method [48]. Negative
130 control principal components were extracted by *minfi* to control for background noise[47]. Batch
131 effect removal was conducted by *combat* after QC [49].

132

133 **Statistical analysis**

134 ***Cocaine survival analysis among HIV-positive participants at baseline.*** Survival analysis
135 was conducted using baseline information among 1,435 HIV-positive participants with cocaine
136 use frequency (0-5) and other covariates (**Figure 1**). Kaplan Meier analyses on 10-year follow-
137 up among HIV-positive and HIV-negative participants by cocaine use frequency (0-5) at
138 baseline was conducted, and the Kaplan Meier curves were plotted by using the R package
139 *survminer* [50]. A test on ordered differences of Kaplan Meier curves by cocaine use frequency
140 was conducted by *survminer* [50].

141

142 To adjust for confounding factors, Cox proportional-hazards model was used to assess the
143 hazard ratio of baseline cocaine use frequency (0-5) on mortality during the follow-up using the
144 R package *survival* [51]. The following model was used to calculate the adjusted hazard ratio
145 among HIV-positive participants.

$$h(t) = h_0(t) \exp(\beta_1 \text{cocaine use frequency} + \beta_2 \text{sex} + \beta_3 \text{baseline age} + \beta_4 \text{race} \\ + \beta_5 \log_{10}(\text{viral load}) + \beta_6 \text{CD4 count} + \beta_7 \text{antiviral medication adherence})$$

146 We then added VACS index to the above model as covariate to assess whether the association
147 of cocaine use frequency with mortality remained significant after adjusting for HIV severity.

148

149 **Association between the cocaine use frequency and HIV severity among HIV-positive**
150 **participants at baseline.** This analysis was conducted using baseline information on cocaine
151 use frequency (0–5), VACS index and other covariates (**Figure 1**). The following linear
152 regression model was performed to test the association of the cocaine use frequency and HIV
153 severity, adjusting for confounders shown in the following model.

HIV disease severity

$$= \beta_1 \text{cocaine use frequency} + \beta_2 \text{sex} + \beta_3 \text{age} + \beta_4 \text{race} \\ + \beta_5 \log_{10}(\text{viral load}) + \beta_6 \text{CD4 count} + \beta_7 \text{antiviral medication adherence}$$

154 **Selection of candidate CpGs by epigenome-wide association (EWA) on persistent**
155 **cocaine use and HIV severity.** To select candidate CpG for mediation analysis, we conducted
156 two separate EWAs on persistent cocaine use and HIV severity (**Figure 1**). Each EWA model
157 adjusted for sex, baseline age, race, smoking, self-reported antiviral medication adherence,
158 white blood cell count, estimated cell type proportions, negative control principal components
159 and residual principal components, and the model details have been described previously [28,
160 46, 52]. Since CD4+ T cell count is one component of VACS index, to avoid overrepresented
161 CpGs associated with CD4+ T cell type in EWA results, we extracted top 1,000 CD4+ T cell
162 type relevant CpGs based on data from *FlowSorted.Blood.450k* [53]. Top 2 principal
163 components that in total account for > 80% variation of the 1,000 CD4+ T cell CpGs were used
164 as covariates in the VACS index EWA model. The significance threshold was arbitrarily set at a
165 more liberal threshold ($p < 0.001$). CpGs with $p < 0.001$ in both EWAs on the persistent cocaine
166 use and HIV severity were selected as candidate CpGs for mediation analyses.

167
168 **Single-site mediation analysis and joint mediation analysis.** The selected candidate CpGs
169 were assessed as potential mediators on the association between persistent cocaine use and
170 HIV severity among HIV-positive participants (N=467). We performed single-site mediation
171 analysis using the R package *mediation*[54].

172 We used M to represent the candidate CpGs (mediator), X to represent persistent cocaine use
173 status (exposure), Y to represent the average VACS index after blood collection (outcome), and
174 C_i to represent k confounding variables (sex, age, race, smoking, self-report antiviral medication
175 adherence, white blood cell count, estimated CD8 T cells, granulocyte, NK cells, B cells,
176 monocytes). The mediator model $f(M|X, C)$ examined the association between persistent
177 cocaine use and CpGs:

$$f(M|X, C) = \beta_0 X + \sum_{i=1}^k \beta_i C_i$$

178 The outcome model $f(Y|X, M, C)$ examined both the direct effect of persistent cocaine use on
179 VACS index and the mediation effect by CpG:

$$f(Y|X, M, C) = \alpha_0 X + \alpha_1 M + \sum_{i=1}^k \alpha_{i+1} C_i$$

180 Thus, the mediation effect of CpG M is $\alpha_1 \beta_0$, the total effect is $\alpha_0 + \alpha_1 \beta_0$ and the proportion
181 mediated is $\alpha_1 \beta_0 / (\alpha_0 + \alpha_1 \beta_0)$. The confidence interval and p-value were estimated by
182 bootstrapping of 1,000,000 iterations.

183

184 The joint mediation analysis on all significant mediator CpGs were conducted as previously
185 described [55]. Assuming the independence between multiple mediators M_1, M_2, \dots, M_n , the
186 mediator model $f(M_j|X, C)$ for M_j is:

$$f(M_j|X, C) = \beta_{0j} X + \sum_{i=1}^k \beta_{ij} C_i$$

187 The outcome model $f(Y|X, M_1, \dots, M_n, C)$ is:

$$f(Y|X, M_1, \dots, M_n, C) = \alpha_0 X + \sum_{j=1}^n \alpha_j M_j + \sum_{i=1}^k \alpha_{i+n} C_i$$

188 The joint mediation effect of CpGs M_1, \dots, M_j is $\sum_{j=1}^n \alpha_j \beta_{0j}$, the total effect is $\alpha_0 + \sum_{j=1}^n \alpha_j \beta_{0j}$, and
189 the proportion mediated is $\sum_{j=1}^n \alpha_j \beta_{0j} / (\alpha_0 + \sum_{j=1}^n \alpha_j \beta_{0j})$. The confidence interval and p-value
190 were estimated by bootstrapping of 1,000,000 iterations.

191
192 **Gene ontology (GO) enrichment analysis.** We performed GO enrichment analysis for genes
193 located near significant mediator CpGs using Database for Annotation, Visualization and
194 Integrated Discovery (DAVID) [56]. To avoid redundancy in pathway names, we only used level
195 4 GO terms defined in DAVID in the enrichment analysis. We considered biological pathways
196 with false discovery rate (FDR) less than 0.05 as statistically significant pathways.

197

198 **Results**

199 **Cocaine use affects HIV severity and mortality among HIV-positive participants.** We found
200 that among HIV-positive participants, higher frequency of cocaine use at baseline was
201 significantly associated with higher VACS index (i.e., higher HIV severity, $p=0.00027$), after
202 adjusting for sex, age, race, viral load, CD4 count and antiviral medication adherence (**Table 2**).
203 Higher cocaine use frequency was also associated with increased mortality ($p=0.008$, **Figure**
204 **2a**). Such difference was not found among HIV-negative participants ($p=0.180$, **Figure 2b**).
205 Using Cox proportional-hazards model, this trend remained significant with a hazard ratio (HR)
206 of 1.10 (95%CI: 1.02-1.19, $p=0.011$), controlling for sex, baseline age, race, viral load, CD4
207 count and antiviral medication adherence (**Table 2**). Interestingly, when VACS index was added
208 to the Cox model, frequency of cocaine use was no longer significantly associated with mortality
209 (HR= 1.076, $p=0.058$), indicating that cocaine's effect on increased mortality may through HIV
210 severity. Our results were consistent with previous findings that cocaine use accelerated HIV
211 progression and increased mortality independent of antiviral medication adherence [5, 6, 9-11].

212

213 ***Selection of candidate DNAm sites for mediation analysis by EWA scan***

214 The EWA scan on persistent cocaine use showed good control of inflation ($\lambda=1.034$, **Figure S1**).

215 A total of 497 CpGs met our candidate selection threshold ($p<0.001$). Interestingly, top ranked

216 CpG site cg22917487 was close to epigenome-wide significance threshold ($p<1.2E-07$) with p-

217 value of $1.69E-07$. This CpG site is located on *CX3CR1*, a gene that encodes a coreceptor for

218 HIV-1 and leads to rapid HIV progression (**Table S1**).

219

220 The EWA scan on VACS index also showed good control of inflation ($\lambda=1.116$, **Figure S1**).

221 There were 876 CpGs that reached candidate selection threshold ($p<0.001$) (**Table S2**). Of note,

222 6 CpGs reached epigenome-wide significance threshold ($p<1.2E-07$). These CpGs were located

223 near the genes involved in viral and immune response (*PARP9*, *IFITM1*, *CD247*, *IFIT3*, *VASN*,

224 *RUNX1*).

225

226 We selected candidate CpGs that were both significantly associated with cocaine use and HIV
227 severity ($p<0.001$) by two separate EWA scans of 408,583 CpGs for mediation analysis.

228 Fourteen CpGs that both met our candidate selection threshold. Additionally, cg22917487 in

229 *CX3CR1* showed strong association with cocaine ($p=1.69E-07$) and marginal association with

230 VACS index ($p=1.73E-03$). Given its biological plausibility, this CpG was also included as a

231 candidate mediator for mediation analysis. Overall, a total of 15 CpGs were selected as

232 candidates to assess their potential mediation roles on the association between persistent

233 cocaine use and HIV severity.

234

235 ***Mediation analysis of candidate CpGs between persistent cocaine use and HIV severity***

236 We examined the mediation role of DNAm between persistent cocaine use and HIV severity

237 (**Figure 1**). Average VACS index after blood collection to ensure that DNAm profiling preceded

238 of HIV severity. Twelve out of the 15 candidate CpGs showed significant mediation effects on

239 the association between persistent cocaine use and VACS index with p-values ranging from
240 1.00E-06 to 0.00307 (**Table 4**). These results remained significant after Bonferroni correction
241 ($p < 0.0033$). Each CpG mediator explained between 11.3% to 29.5% of persistent cocaine use
242 affecting HIV severity. These 12 CpGs collectively mediated 47.2% of the cocaine's effects on
243 the HIV severity.

244
245 Significant mediator CpGs are located near 11 viral and immune response genes: *MX1*, *PARP9*,
246 *IFIT3*, *IFITM1*, *NLRC5*, *EPSTI1*, *PLSCR1*, *TAP2*, *TAP1*, *CX3CR1* and *RIN2*. Five CpGs are
247 located on 5' gene regulatory region, 4 CpGs on gene body, 2 CpGs on transcription start sites
248 and 1 CpG on 3' gene regulatory region. Notably, these 12 CpGs were mostly less methylated
249 in persistent cocaine use group compared to never cocaine use group (**Table 3, Figure 3**).

250 **Figure 4** illustrates the mediation effect of cg26312951 (*MX1*), cg08122652 (*PARP9*),
251 cg07839457 (*NLRC5*) and cg22917487 (*CX3CR1*) on persistent cocaine use affecting HIV
252 severity.

253

254 **Biological pathways**

255 Twelve significant CpG mediators were annotated to 11 genes. These genes were significantly
256 enriched in 6 biological pathways (**Table 5**). These significant pathways were viral process
257 ($p = 7.76E-08$), response to cytokine ($p = 9.88E-07$), defense response to virus ($p = 4.40E-06$),
258 regulation of viral process ($p = 7.50E-06$), response to type I interferon ($p = 8.49E-06$) and
259 response to virus ($p = 1.48E-05$).

260

261 **Discussion**

262 Our findings provide evidence that cocaine use worsens HIV severity and increases mortality
263 among HIV-1 positive participants, and cocaine's adverse effect is mediated by DNAm in blood.

264 We identified 12 CpGs that collectively accounted for a total of 47.2% cocaine use's adverse

Shu et al, CID

DNAm mediates cocaine exposure on HIV

265 effect on HIV severity. These CpGs, which are enriched in viral process and inflammatory
266 response pathways, offer new insights into the mechanisms of how cocaine use may affect HIV
267 outcomes through DNAm.

268

269 These 12 CpGs are located in or near 11 biologically meaningful genes that were previously
270 reported to be involved in inflammation, HIV-1 viral replication and other pathways that play
271 critical roles in HIV progression. Specifically, cg06188083 on *IFIT3* mediated 28.8% of the
272 variation, and *IFIT3* encodes an IFN-induced antiviral protein which acts as an inhibitor of viral
273 processes and viral replication[57]. Another significant mediator CpG site, cg06188083, is
274 located near interferon gene *IFITM1*. We previously reported hypomethylation of cg07839457
275 due to HIV infection, which is located in the promoter region of *NLRC5* [28]. This CpG site was
276 also a significant mediator between cocaine and HIV severity in this study. *NLRC5* plays an
277 important role in cytokine response and antiviral immunity through its inhibition of NF-kappa-B
278 activation and negative regulation of type I interferon signaling pathways[58]. The converging
279 evidence on cg07839457 (*NLRC5*) warrants further investigation of its role in HIV infection and
280 progression. Another interesting CpG site, cg22917487 on *CX3CR1*, showed both strong
281 association with persistent cocaine use and significant mediation effect of cocaine affecting HIV
282 severity. *CX3CR1* is involved in leukocyte adhesion and migration and was recently identified as
283 an HIV-1 coreceptor [59]. Some studies also showed that genetic variants on *CX3CR1* were
284 associated with HIV susceptibility and rapid HIV progression to AIDS[60]. cg25114611, located
285 in the promoter region of *FKBP5*, is also biologically plausible, given the implication for chronic
286 cocaine administration upregulating *FKBP5* expression in rats [61].

287

288 The joint mediation effect of the 12 CpGs was less than the total sum of the mediation effects
289 across the individual CpG. This result suggests that the mediation effect for 12 CpGs were not

290 entirely independent. CpGs located in the same gene or the biological pathways may
291 collectively mediate cocaine use on HIV severity.

292

293 There are several strengths of this study. First, instead of selecting candidate mediator CpGs
294 based on literature or hypotheses, we applied an unbiased epigenome-wide screening to select
295 CpGs associated with both cocaine use and HIV severity. Second, to limit self-reporting bias of
296 cocaine use, we leveraged longitudinal data in defining persistent cocaine use and never
297 cocaine use. We included only those participants who consistently reported cocaine use or no
298 cocaine use across all 5 visits for the selection of candidate CpGs and the mediation analyses.
299 Lastly, we used the average VACS index after blood collection so that DNAm
300 measurements(mediator) preceded HIV severity(outcome) for the mediation analyses.

301

302 One limitation of the study is that our sample size on mediation analyses is small. However, the
303 strict definition of cocaine use helped reduced self-reporting bias and can potentially increase
304 power by comparing extreme groups. Additionally, our samples consisted of mostly male
305 veterans, which may limit the generalizability of our findings.

306

307 In summary, we validated previous reports that use of cocaine worsened HIV severity and
308 increased risk of all-cause mortality among HIV positive participants. More importantly, this
309 study, for the first time, found that several biologically meaningful DNAm sites mediated the
310 adverse effect of cocaine use on HIV severity. These results merit future studies to further
311 explore the biological mechanisms revealed by these DNAm sites on how cocaine affects HIV
312 disease outcomes.

313

314 **Tables**

315 **Table 1: Sample characteristics in HIV-positive participants**

	Baseline*	Follow-up (time of blood collection)†
Sample size	1435	875
Age [mean (sd)]	48.8 (8.1)	51.5 (7.7)
Sex		
Male	1399 (97.5%)	861 (98.4%)
Female	36 (2.5%)	14 (1.6%)
Race		
Caucasian	290 (20.2%)	84 (9.6%)
African American	964 (67.2%)	726 (83.0%)
Other	181 (12.6%)	65 (7.4%)
Persistent Cocaine use status		
Persistent cocaine use		265 (30.3%)
Non-cocaine use		202 (23.1%)
Cocaine use at baseline (%)		
have never tried	555 (38.7%)	
no use in the last year	540 (37.6%)	
less than once a month	122 (8.5%)	
1-3 times a month	103 (7.2%)	
1-3 times a week	39 (2.7%)	
≥4 times a week	76 (5.3%)	
Cigarette smoking	762 (53.1%)	521 (59.5%)
VACS index‡	30.0 (19.1)	
Average VACS index after blood collection[mean(sd)]		39.20 (22.4)
CD4+ count [mean (sd)]	418.7 (273.0)	440.02 (289.1)
log10 viral load [mean (sd)]	3.1 (1.2)	2.74 (1.2)
Antiviral medication adherence (%)	1117 (77.8%)	666 (76.1%)

*Samples at baseline for the survival analysis

†A subset of samples at the time of blood collection with DNA methylation measurements

‡VACS index: Veteran Aging Cohort Study index

Table 2: Association between cocaine use frequency and HIV severity and survival analysis among HIV-positive participants

	HIV severity [*]				Mortality [†]			
	Estimate	SE	T	P value	Hazard ratio	95% CI	Z	P value
Cocaine use frequency [‡]	1.00	0.28	3.65	2.70E-04	1.10	(1.02,1.19)	2.54	1.10E-02
Sex (reference: male)	5.78	2.33	2.48	1.34E-02	0.27	(0.07,1.08)	-1.86	6.33E-02
Age [‡]	1.09	0.05	23.58	< 2E-16	1.05	(1.04,1.07)	7.35	1.90E-13
Race (reference: Caucasian)								
African American	7.30	0.94	7.73	2.00E-14	1.05	(0.80,1.39)	0.37	7.15E-01
Other	5.33	1.31	4.08	4.80E-05	0.71	(0.47,1.09)	-1.57	1.17E-01
log 10 viral load [‡]	4.72	0.36	13.11	< 2eE-16	1.07	2	1.36	1.73E-01
CD4 count [‡]	-0.03	0.00	-19.05	< 2E-16	1.00	(1.00,1.00)	-3.74	1.80E-04
Antiviral medication adherence [‡]	2.59	0.99	2.62	8.87E-03	1.02	(0.76,1.37)	0.13	8.95E-01

^{*}Summary statistics from linear regression model

[†]Summary statistics from Cox proportional hazards model

[‡]Measured at baseline

317

Table 3: Epigenome-wide association(EWA) scan to select candidate CpGs

CpG	Chr	Position	Nearest gene	Cocaine EWA effect size	Cocaine EWA p-value	VACS index* EWA effect size	VACS index* EWA p-value	Reference Gene Group	Relations to CpG Islands
cg22917487	3	39322103	<i>CX3CR1</i>	1.71E-02	1.69E-07	1.96E-04	1.73E-03	Body;TSS200;5UTR;TSS1500	
cg07839457	16	57023022	<i>NLRC5</i>	-5.18E-02	3.16E-05	-7.08E-04	4.02E-04	TSS1500	N_Shore
cg26312951	21	42797847	<i>MX1</i>	-3.93E-02	3.24E-05	-7.80E-04	2.50E-07	TSS200;5UTR	N_Shore
cg06188083	10	91093005	<i>IFIT3</i>	-5.06E-02	3.34E-05	-9.96E-04	4.76E-08	Body	
cg08122652	3	1.22E+08	<i>PARP9</i>	-6.13E-02	1.10E-04	-1.26E-03	2.30E-10	5UTR;TSS1500	N_Shore
cg22385827	2	2.11E+08	<i>C2orf67</i>	8.10E-03	2.01E-04	1.20E-04	7.52E-04	0	Island
cg22930808	3	1.22E+08	<i>PARP9</i>	-6.52E-02	2.44E-04	-1.17E-03	1.52E-06	TSS1500	N_Shore
cg06981309	3	1.46E+08	<i>PLSCR1</i>	-4.29E-02	2.63E-04	-5.72E-04	4.21E-04	5UTR;TSS1500	N_Shore
cg03753191	13	43566902	<i>EPSTI1</i>	-1.36E-02	2.81E-04	-2.44E-04	5.50E-05	0	S_Shore
cg00096307	2	1.07E+08	<i>UXS1</i>	-1.12E-02	3.59E-04	1.74E-04	5.73E-04	TSS1500	
cg26396492	20	19915762	<i>RIN2</i>	-1.26E-02	4.76E-04	-2.00E-04	9.15E-04	Body	
cg22940798	6	32805554	<i>TAP2</i>	-1.93E-02	4.82E-04	-2.89E-04	4.72E-04	Body	N_Shore
cg08623256	5	3858275		-1.73E-02	6.96E-04	3.17E-04	7.18E-04		S_Shelf
cg08818207	6	32820355	<i>TAP1</i>	-2.67E-02	8.18E-04	-6.18E-04	2.11E-07	Body	N_Shore
cg03038262	11	315262	<i>IFITM1</i>	-2.98E-02	9.59E-04	-6.46E-04	7.65E-09	3UTR	N_Shore

*VACS index: Veteran Aging Cohort Study index

318

319

320

321 **Table 4: Mediation analyses on candidate CpGs between cocaine use and VACS index***

CpG	Chr	Position	Nearest gene	Reference Gene Group	Relations to CpG Islands	Average Causal Mediation Effect			Proportion Mediated			Average Direct Effect	Total Effect
						Effect estimate	95% CI	p value	Proportion Mediated	95% CI	p value		
cg26312951	21	42797847	<i>MX1</i>	TSS200;5UTR	N_Shore	0.097	(0.051,0.153)	1.00E-06	29.5%	(15.9%,53.0%)	1.00E-06	0.231	0.329
cg08122652	3	122281939	<i>PARP9</i>	5UTR;TSS1500	N_Shore	0.092	(0.049,0.142)	1.00E-06	28.2%	(15.7%,49.2%)	1.00E-06	0.236	0.329
cg06188083	10	91093005	<i>IFIT3</i>	Body		0.095	(0.052,0.145)	2.00E-06	28.8%	(16.2%,50.7%)	2.00E-06	0.234	0.329
cg03038262	11	315262	<i>IFITM1</i>	3UTR	N_Shore	0.078	(0.040,0.123)	4.00E-06	23.7%	(12.4%,42.8%)	4.00E-06	0.251	0.329
cg07839457	16	57023022	<i>NLRC5</i>	TSS1500	N_Shore	0.079	(0.038,0.127)	8.00E-06	24.0%	(11.0%,47.5%)	8.00E-06	0.250	0.329
cg22930808	3	122281881	<i>PARP9</i>	5UTR;TSS1500	N_Shore	0.091	(0.047,0.141)	8.00E-06	27.7%	(15.1%,48.9%)	8.00E-06	0.237	0.329
cg03753191	13	43566902	<i>EPSTI1</i>	TSS1500	S_Shore	0.078	(0.036,0.128)	3.90E-05	23.7%	(10.6%,46.8%)	3.90E-05	0.251	0.329
cg06981309	3	146260954	<i>PLSCR1</i>	5UTR	N_Shore	0.074	(0.033,0.123)	4.70E-05	22.6%	(10.7%,41.8%)	4.70E-05	0.254	0.329
cg22940798	6	32805554	<i>TAP2</i>	Body	N_Shore	0.058	(0.025,0.100)	5.70E-05	17.6%	(7.6%,35.6%)	5.70E-05	0.271	0.329
cg08818207	6	32820355	<i>TAP1</i>	Body	N_Shore	0.081	(0.037,0.130)	5.80E-05	24.5%	(11.9%,44.7%)	5.90E-05	0.248	0.329
cg22917487	3	39322103	<i>CX3CR1</i>	Body;TSS200;5UTR;TSS1500		0.054	(0.015,0.104)	1.81E-03	16.3%	(4.6%,34.4%)	1.81E-03	0.276	0.329
cg26396492	20	19915762	<i>RIN2</i>	Body		0.037	(0.009,0.073)	3.07E-03	11.3%	(2.7%,24.9%)	3.07E-03	0.291	0.329

322
 323 *VACS index: Veteran Aging Cohort Study index
 324

325

Table 5: Gene ontology (GO) pathway enrichment analysis and joint mediation effect

Term	n	%	P value	Genes	CpG	Fold Enrichment	FDR*
GO:0016032~viral process	8	73	7.76E-08	<i>PLSCR1, CX3CR1, IFITM1, IFIT3, MX1, TAP2, NLRC5, TAP1</i>	cg06981309, cg22917487, cg03038262, cg06188083, cg26312951, cg22940798, cg07839457, cg08818207	15.1	9.89E-05
GO:0034097~response to cytokine	7	64	9.88E-07	<i>PARP9, PLSCR1, CX3CR1, IFITM1, IFIT3, MX1, NLRC5</i>	cg08122652, cg06981309, cg22917487, cg03038262, cg06188083, cg26312951, cg07839457	15.9	1.26E-03
GO:0051607~defense response to virus	5	45	4.40E-06	<i>PLSCR1, IFITM1, IFIT3, MX1, NLRC5</i>	cg06981309, cg03038262, cg06188083, cg26312951, cg07839457	39.8	5.61E-03
GO:0050792~regulation of viral process	5	45	7.50E-06	<i>PLSCR1, IFITM1, MX1, TAP2, TAP1</i>	cg06981309, cg03038262, cg26312951, cg22940798, cg08818207	34.8	9.56E-03
GO:0034340~response to type I interferon	4	36	8.49E-06	<i>IFITM1, IFIT3, MX1, NLRC5</i>	cg03038262, cg06188083, cg26312951, cg07839457	93.5	1.08E-02
GO:0009615~response to virus	5	45	1.48E-05	<i>PLSCR1, IFITM1, IFIT3, MX1, NLRC5</i>	cg06981309, cg03038262, cg06188083, cg26312951, cg07839457	29.3	1.88E-02

* FDR: False discovery rate

326
327

328 **Figure Legends**

329

330 **Figure 1.** Timeline of data and blood sample collection for each analysis

331 **Figure 2.** Kaplan Meier curves by cocaine use frequency at baseline among HIV-positive

332 (n=1,463) and HIV-negative (n=795) participants. The higher frequency of cocaine use is

333 associated with lower survival probability among HIV-positive participants, but not among HIV-

334 negative participants.

335 **Figure 3.** DNA methylation level of the selected CpG mediators by persistent cocaine use

336 status

337 **Figure 4.** Significant mediation effect of cg26312951 (*MX1*), cg08122652 (*PARP9*), cg07839457

338 (*NLRC5*) and cg22917487 (*CX3CR1*) between persistent cocaine use and HIV severity

339 ($p < 0.0033$)

340 **Figure S1:** Manhattan and quantile-quantile (QQ) plot of persistent cocaine use epigenome-

341 wide association (EWA) ($\lambda = 1.034$) and HIV severity EWA ($\lambda = 1.116$)

342

343 **Declarations**

344 ***Ethics approval and consent to participate***

345 The study was approved by the committee of the Human Research Subject Protection at Yale

346 University and the Institutional Research Board Committee of the Connecticut Veteran

347 Healthcare System. All participants provided written consents.

348 ***Availability of data and materials***

349 Demographic and clinical variables and DNAm data for the VACS samples were submitted to

350 GEO dataset (GSE117861) and are available to the public. All codes for analysis are also

351 available upon a request to the corresponding author.

352 ***Conflict of interest***

353 All authors declare that they have no conflict of interest.

354 **Funding**

355 The work was supported by the National Institute on Drug Abuse (R03DA039745,

356 R01DA038632, R01DA047063, R01DA047820).

357 **Authors' contributions**

358 CS was responsible for data analysis and manuscript preparation. ACJ provided DNA samples,

359 clinical data, and contributed to manuscript preparation. XZ was responsible for the

360 bioinformatics data processing. ZW contributed to mediation analysis and manuscript

361 preparation. DH and EJ contributed to analytical approach and the manuscript preparation. KX

362 was responsible for the study design, study protocol, sample preparation, data analysis,

363 interpretation of findings, and manuscript preparation.

364 **Acknowledgements** The authors appreciate the support of the Veteran Aging Study Cohort

365 Biomarker Core and Yale Center of Genomic Analysis

366

367 **Reference**

- 368 1. Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and
369 HIV infection in intravenous drug users in San Francisco. *Jama* **1989**; 261(4): 561-5.
- 370 2. Tyndall MW, Currie S, Spittal P, et al. Intensive injection cocaine use as the primary risk
371 factor in the Vancouver HIV-1 epidemic. *Aids* **2003**; 17(6): 887-93.
- 372 3. Webber MP, Schoenbaum EE, Gourevitch MN, Buono D, Klein RS. A prospective study
373 of HIV disease progression in female and male drug users. *Aids* **1999**; 13(2): 257-62.
- 374 4. Vittinghoff E, Hessel NA, Bacchetti P, Fusaro RE, Holmberg SD, Buchbinder SP.
375 Cofactors for HIV disease progression in a cohort of homosexual and bisexual men.
376 *Journal of acquired immune deficiency syndromes (1999)* **2001**; 27(3): 308-14.
- 377 5. Cook JA, Burke-Miller JK, Cohen MH, et al. Crack cocaine, disease progression, and
378 mortality in a multi-center cohort of HIV-1 positive women. *AIDS (London, England)* **2008**;
379 22(11): 1355.
- 380 6. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates
381 HIV disease progression in a cohort of HIV-positive drug users. *JAIDS Journal of*
382 *Acquired Immune Deficiency Syndromes* **2009**; 50(1): 93-9.
- 383 7. Sharpe TT, Lee LM, Nakashima AK, Elam-Evans LD, Fleming PL. Crack cocaine use
384 and adherence to antiretroviral treatment among HIV-infected black women. *J*
385 *Community Health* **2004**; 29(2): 117-27.
- 386 8. Cofrancesco Jr J, Scherzer R, Tien PC, et al. Illicit drug use and HIV treatment
387 outcomes in a US cohort. *AIDS (London, England)* **2008**; 22(3): 357.
- 388 9. Carrico AW, Johnson MO, Morin SF, et al. Stimulant use is associated with immune
389 activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy.
390 *Brain, behavior, and immunity* **2008**; 22(8): 1257-62.
- 391 10. Dash S, Balasubramaniam M, Villalta F, Dash C, Pandhare J. Impact of cocaine abuse
392 on HIV pathogenesis. *Front Microbiol* **2015**; 6: 1111-.
- 393 11. Rasbach DA, Desruisseau AJ, Kipp AM, et al. Active cocaine use is associated with lack
394 of HIV-1 virologic suppression independent of nonadherence to antiretroviral therapy:
395 use of a rapid screening tool during routine clinic visits. *AIDS care* **2013**; 25(1): 109-17.
- 396 12. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related
397 differential DNA methylation: 27K discovery and replication. *The American Journal of*
398 *Human Genetics* **2011**; 88(4): 450-7.
- 399 13. Joubert BR, Håberg SE, Nilsen RM, et al. 450K epigenome-wide scan identifies
400 differential DNA methylation in newborns related to maternal smoking during pregnancy.
401 *Environmental health perspectives* **2012**; 120(10): 1425-31.
- 402 14. Lee KW, Pausova Z. Cigarette smoking and DNA methylation. *Frontiers in genetics*
403 **2013**; 4: 132.
- 404 15. Tsaprouni LG, Yang T-P, Bell J, et al. Cigarette smoking reduces DNA methylation
405 levels at multiple genomic loci but the effect is partially reversible upon cessation.
406 *Epigenetics* **2014**; 9(10): 1382-96.
- 407 16. Gao X, Zhang Y, Saum K-U, Schöttker B, Breitling LP, Brenner H. Tobacco smoking and
408 smoking-related DNA methylation are associated with the development of frailty among
409 older adults. *Epigenetics* **2017**; 12(2): 149-56.
- 410 17. Zhang X, Hu Y, Aouizerat BE, et al. Machine learning selected smoking-associated DNA
411 methylation signatures that predict HIV prognosis and mortality. **2018**; 10(1): 155.
- 412 18. Zhang R, Miao Q, Wang C, et al. Genome-wide DNA methylation analysis in alcohol
413 dependence. *Addiction biology* **2013**; 18(2): 392-403.
- 414 19. Zhang H, Gelernter J. DNA methylation and alcohol use disorders: Progress and
415 challenges. *The American journal on addictions* **2017**; 26(5): 502-15.

- 416 20. Sharp GC, Arathimos R, Reese SE, et al. Maternal alcohol consumption and offspring
417 DNA methylation: findings from six general population-based birth cohorts. *Epigenomics*
418 **2018**; 10(1): 27-42.
- 419 21. Liu C, Marioni RE, Hedman ÅK, et al. A DNA methylation biomarker of alcohol
420 consumption. *Molecular psychiatry* **2018**; 23(2): 422.
- 421 22. Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators
422 in cancer aetiology and progression. *Nature Reviews Genetics* **2016**; 17: 284.
- 423 23. Hao X, Luo H, Krawczyk M, et al. DNA methylation markers for diagnosis and prognosis
424 of common cancers. *Proceedings of the National Academy of Sciences* **2017**; 114(28):
425 7414.
- 426 24. Michalak EM, Burr ML, Bannister AJ, Dawson MA. The roles of DNA, RNA and histone
427 methylation in ageing and cancer. *Nature Reviews Molecular Cell Biology* **2019**.
- 428 25. Davegårdh C, García-Calzón S, Bacos K, Ling C. DNA methylation in the pathogenesis
429 of type 2 diabetes in humans. *Mol Metab* **2018**; 14: 12-25.
- 430 26. Zhong J, Agha G, Baccarelli AA. The role of DNA methylation in cardiovascular risk and
431 disease: methodological aspects, study design, and data analysis for epidemiological
432 studies. *Circulation research* **2016**; 118(1): 119-31.
- 433 27. Nakatochi M, Ichihara S, Yamamoto K, et al. Epigenome-wide association of myocardial
434 infarction with DNA methylation sites at loci related to cardiovascular disease. *Clinical*
435 *epigenetics* **2017**; 9(1): 54.
- 436 28. Zhang X, Justice AC, Hu Y, et al. Epigenome-wide differential DNA methylation between
437 HIV-infected and uninfected individuals. *Epigenetics* **2016**; 11(10): 750-60.
- 438 29. Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA
439 methylation as an intermediary of genetic risk in rheumatoid arthritis. *Nature*
440 *biotechnology* **2013**; 31(2): 142.
- 441 30. Bind M-A, Lepeule J, Zanobetti A, et al. Air pollution and gene-specific methylation in the
442 Normative Aging Study: association, effect modification, and mediation analysis.
443 *Epigenetics* **2014**; 9(3): 448-58.
- 444 31. Cao-Lei L, Dancause KN, Elgbeili G, et al. DNA methylation mediates the impact of
445 exposure to prenatal maternal stress on BMI and central adiposity in children at age 13½
446 years: Project Ice Storm. *Epigenetics* **2015**; 10(8): 749-61.
- 447 32. Timms JA, Relton CL, Rankin J, Strathdee G, McKay JA. DNA methylation as a potential
448 mediator of environmental risks in the development of childhood acute lymphoblastic
449 leukemia. *Epigenomics* **2016**; 8(4): 519-36.
- 450 33. Tobi EW, Slieker RC, Luijk R, et al. DNA methylation as a mediator of the association
451 between prenatal adversity and risk factors for metabolic disease in adulthood. *Science*
452 *advances* **2018**; 4(1): eaao4364.
- 453 34. Barker ED, Walton E, Cecil CA. Annual Research Review: DNA methylation as a
454 mediator in the association between risk exposure and child and adolescent
455 psychopathology. *Journal of Child Psychology and Psychiatry* **2018**; 59(4): 303-22.
- 456 35. Rutten BPF, Mill J. Epigenetic Mediation of Environmental Influences in Major Psychotic
457 Disorders. *Schizophrenia Bulletin* **2009**; 35(6): 1045-56.
- 458 36. Jordahl KM, Phipps AI, Randolph TW, et al. Differential DNA methylation in blood as a
459 mediator of the association between cigarette smoking and bladder cancer risk among
460 postmenopausal women. *Epigenetics* **2019**: 1-9.
- 461 37. Shirazi J, Shah S, Sagar D, et al. Epigenetics, drugs of abuse, and the retroviral
462 promoter. *J Neuroimmune Pharmacol* **2013**; 8(5): 1181-96.
- 463 38. Dhillon NK, Williams R, Peng F, et al. Cocaine-mediated enhancement of virus
464 replication in macrophages: implications for human immunodeficiency virus-associated
465 dementia. *J Neurovirol* **2007**; 13(6): 483-95.

- 466 39. Justice AC, Dombrowski E, Conigliaro J, et al. Veterans aging cohort study (VACS):
467 overview and description. **2006**; 44(8 Suppl 2): S13.
- 468 40. Veterans Aging Cohort Study. VACS Biomarker Cohort Description. **2016**.
- 469 41. Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for
470 mortality after one year of antiretroviral therapy. *AIDS (London, England)* **2013**; 27(4):
471 563-72.
- 472 42. Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort
473 Study index for mortality with HIV infection: a North American cross cohort analysis.
474 *Journal of acquired immune deficiency syndromes (1999)* **2013**; 62(2): 149-63.
- 475 43. Bebu I, Tate J, Rimland D, et al. The VACS Index Predicts Mortality in a Young, Healthy
476 HIV Population Starting Highly Active Antiretroviral Therapy. *J Acquir Immune Defic*
477 *Syndr* **2014**; 65(2): 226-30.
- 478 44. Brown ST, Tate JP, Kyriakides TC, et al. The VACS index accurately predicts mortality
479 and treatment response among multi-drug resistant HIV infected patients participating in
480 the options in management with antiretrovirals (OPTIMA) study. *PLoS One* **2014**; 9(3):
481 e92606.
- 482 45. Justice AC, Modur S, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort
483 Study (VACS) index for mortality with HIV infection: a north American cross cohort
484 analysis. *Journal of acquired immune deficiency syndromes (1999)* **2013**; 62(2): 149.
- 485 46. Lehne B, Drong AW, Loh M, et al. A coherent approach for analysis of the Illumina
486 HumanMethylation450 BeadChip improves data quality and performance in epigenome-
487 wide association studies. **2015**; 16(1): 37.
- 488 47. Aryee MJ, Jaffe AE, Corrada-Bravo H, et al. Minfi: a flexible and comprehensive
489 Bioconductor package for the analysis of Infinium DNA methylation microarrays. **2014**;
490 30(10): 1363-9.
- 491 48. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as
492 surrogate measures of cell mixture distribution. *BMC Bioinformatics* **2012**; 13(1): 86.
- 493 49. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data
494 using empirical Bayes methods. *Biostatistics* **2007**; 8(1): 118-27.
- 495 50. Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using 'ggplot2'.
496 R package version 03 **2017**; 1.
- 497 51. Therneau T. A Package for Survival Analysis in S. version 2.38. **2015**.
- 498 52. Zhang X, Hu Y, Justice AC, et al. DNA methylation signatures of illicit drug injection and
499 hepatitis C are associated with HIV frailty. *Nature Communications* **2017**; 8(1): 2243.
- 500 53. Jaffe A. Flowsorted. blood. 450k: illumina humanmethylation data on sorted blood cell
501 populations. R Package Version **2015**; 1(0).
- 502 54. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. Mediation: R package for causal
503 mediation analysis. **2014**.
- 504 55. VanderWeele T, Vansteelandt S. Mediation analysis with multiple mediators.
505 *Epidemiologic methods* **2014**; 2(1): 95-115.
- 506 56. Fresno C, Fernández EAJB. RDAVIDWebService: a versatile R interface to DAVID.
507 **2013**; 29(21): 2810-1.
- 508 57. Schmeisser H, Mejido J, Balinsky CA, et al. Identification of alpha interferon-induced
509 genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a
510 novel antiviral gene. *J Virol* **2010**; 84(20): 10671-80.
- 511 58. Cui J, Zhu L, Xia X, et al. NLRC5 negatively regulates the NF-kappaB and type I
512 interferon signaling pathways. *Cell* **2010**; 141(3): 483-96.
- 513 59. Garin A, Tarantino N, Faure S, et al. Two novel fully functional isoforms of CX3CR1 are
514 potent HIV coreceptors. *J Immunol* **2003**; 171(10): 5305-12.

Shu et al, CID

DNAm mediates cocaine exposure on HIV

- 515 60. Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HIV+ individuals
516 with a structural variant of the chemokine receptor CX3CR1. *Science* **2000**; 287(5461):
517 2274-7.
- 518 61. Connelly KL, Unterwald EM. Chronic cocaine administration upregulates FKBP5 in the
519 extended amygdala of male and female rats. *Drug Alcohol Depend* **2019**; 199: 101-5.
520






Figure 1. Timeline of data and blood sample collection for each analysis



a. HIV-Positive



b. HIV-Negative

Figure 2. Kaplan Meier curves by cocaine use frequency at baseline among HIV positive (n=1435) and HIV negative (n=795) participants




Figure 3. DNA methylation level of the selected CpG mediators by persistent cocaine use status




Figure 4. Significant mediation effect of cg26312951 (*MX1*), cg08122652 (*PARP9*), cg07839457 (*NLRC5*) and cg22917487 (*CX3CR1*) between persistent cocaine use and HIV severity ($p < 0.0033$)